Ajanta Pharma Revenue History — Quarter by Quarter

Ajanta Pharma's revenue moved from ₹1,021 Cr in Q1 FY24 to ₹1,422 Cr in Q4 FY26, a 39.3% change over 12 quarters. The table keeps each quarter linked back to the underlying earnings page.

Revenue by Quarter

Quarter	Revenue (₹ Cr)	YoY Change
Q4 FY26	₹1,422 Cr	+21%
Q3 FY26	₹1,375 Cr	+20%
Q2 FY26	₹1,354 Cr	+14%
Q1 FY26	₹1,303 Cr	+14%
Q4 FY25	₹1,170 Cr	+11%
Q3 FY25	₹1,146 Cr	+4%
Q2 FY25	₹1,187 Cr	+15%
Q1 FY25	₹1,145 Cr	+12%
Q4 FY24	₹1,054 Cr	+20%
Q3 FY24	₹1,105 Cr	+14%
Q2 FY24	₹1,028 Cr	+10%
Q1 FY24	₹1,021 Cr	+7%

What management said about revenue

Q4 FY26 · Revenue growth of high-teens for FY27

Management expects overall revenue growth in the high-teens range, driven by recovery in Asia and Africa, while US generics moderate.

Q4 FY26 · US generics mid-single-digit growth in FY27

US generics expected to grow at mid-single digits due to high base and seasonal flu product impact; 4-5 new launches planned in H2.

Q3 FY26 · US generics double-digit growth in FY27

Management expects US generics to post double-digit growth in FY27, though growth rate may moderate from FY26 levels.

Q2 FY26 · US generics to sustain current run rate in H2

US generics revenue run rate of ~INR 343 crore per quarter is expected to be sustained for the next two quarters.

Q2 FY26 · Africa business to achieve double-digit growth in FY26

Africa business guidance upgraded from mid-single-digit to double-digit growth for the full year.

Q1 FY26 · US generics run-rate to sustain at current level for FY26

Management expects the current quarterly run-rate of ~INR 310 crore to continue for the remaining three quarters, supported by existing limited-competition products and 2-3 more launches planned.

Q1 FY26 · India business to grow 20-25% higher than IPM growth

India business aims to grow at 10%+ if IPM grows at 8%, maintaining its outperformance trajectory.

Q4 FY25 · FY26 Revenue Growth: Branded generics low-teens, US generics high-teens

Management expects branded generic business to grow in low teens and US generics in high teens, driven by new product launches and market share gains.

Q4 FY25 · FY26 ANDA Filings: 10-12 filings

Management expects to file 10-12 ANDAs in FY26, with a robust pipeline and several products in advanced stages.

Q3 FY25 · U.S. generics double-digit growth in FY26

Management guided for double-digit growth in U.S. generics next fiscal year, driven by new launches including 2-3 limited competition products.

Q3 FY25 · R&D spend at 5% of revenue for FY25

R&D expenses are expected to remain at 5% of total revenue for the fiscal year.

Q2 FY25 · Branded generics mid-teens growth for FY25

Management expects branded generics (India, Asia, Africa) to grow in mid-teens for the full year, with Asia and Africa growth moderating in H2.